Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 6, Pages 1965-1967Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI64120
Keywords
-
Categories
Ask authors/readers for more resources
A promising approach to cancer therapy is to elicit apoptosis with BH3 mimetic drugs, which target proteins of the BCL-2 family. As of yet, however, such drugs can target only certain BCL-2 family proteins. Hence, in this issue of the JCI, LaBelle et al. assess instead the therapeutic potential of a stapled BH3 peptide from the BIM protein, which inactivates all its prosurvival relatives. The peptide killed cultured hematologic tumor cells and abated growth of a leukemia xenograft, without perturbing the hematopoietic compartment. Hence, such peptides might eventually provide a new way to treat refractory leukemias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available